[HTML][HTML] Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges

I Kerkis, MS Haddad, CW Valverde… - Stem Cell Research & …, 2015 - Springer
Huntington's disease (HD) is an inherited disease that causes progressive nerve cell
degeneration. It is triggered by a mutation in the HTT gene that strongly influences functional …

[HTML][HTML] Behavioral-and blood-based biomarkers for huntington's disease: Studies on the R6/1 mouse model with prospects for early diagnosis and monitoring of the …

M Podlacha, K Pierzynowska, L Gaffke… - Brain, Behavior, & …, 2022 - Elsevier
Background Huntington's disease (HD) is a genetic neurodegenerative disorder
characterized by a triad of cognitive, psychiatric and motor symptoms. One of the main …

Point-of-care devices using disease biomarkers to diagnose neurodegenerative disorders

TY Wei, Y Fu, KH Chang, KJ Lin, YJ Lu… - Trends in …, 2018 - cell.com
Neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases
are highly prevalent and immensely destructive to the health and well-being of individuals …

[HTML][HTML] Precision medicine in neurology: the inspirational paradigm of complement therapeutics

M Gavriilaki, VK Kimiskidis, E Gavriilaki - Pharmaceuticals, 2020 - mdpi.com
Precision medicine has emerged as a central element of healthcare science. Complement, a
component of innate immunity known for centuries, has been implicated in the …

[HTML][HTML] Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease

YC Huang, YR Wu, MY Tseng, YC Chen, SY Hsieh… - PloS one, 2011 - journals.plos.org
Huntington's disease (HD) is a progressive neurodegenerative disease caused by an
unstable CAG trinucleotide repeat expansion. The need for biomarkers of onset and …

[HTML][HTML] Mouse models of polyglutamine diseases: review and data table. Part I

M Figiel, WJ Szlachcic, PM Switonski, A Gabka… - Molecular …, 2012 - Springer
Polyglutamine (polyQ) disorders share many similarities, such as a common mutation type in
unrelated human causative genes, neurological character, and certain aspects of …

Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease

KV Sathyasaikumar, EK Stachowski… - Journal of …, 2010 - Wiley Online Library
J. Neurochem.(2010) 113, 1416–1425. Abstract Elevated concentrations of neurotoxic
metabolites of the kynurenine pathway (KP) of tryptophan degradation may play a causative …

Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases

C Gibrat, F Cicchetti - Progress in Neuro-Psychopharmacology and …, 2011 - Elsevier
Neurodegenerative disorders are a subset of disabling pathologies characterized, in part, by
a progressive and specific loss of certain brain cell populations. Current therapeutic …

[HTML][HTML] Interleukin-6 deficiency exacerbates Huntington's disease model phenotypes

MH Wertz, SS Pineda, H Lee, R Kulicke… - Molecular …, 2020 - Springer
Huntington's disease (HD) is an incurable neurodegenerative disorder caused by CAG
trinucleotide expansions in the huntingtin gene. Markers of both systemic and CNS immune …

[HTML][HTML] Uric acid as a potential peripheral biomarker for disease features in Huntington's patients

J Corey-Bloom, A Haque, S Aboufadel… - Frontiers in …, 2020 - frontiersin.org
Oxidative stress has long been implicated in the pathophysiology and progression of
Huntington's disease (HD). Uric acid (UA) is a naturally occurring antioxidant that is present …